AOD-9604 is not an FDA-approved drug. It carries no approved indication for obesity, for joints, or for anything else in the United States.
The compounding question is more specific than legal or illegal. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded medication qualifies for the statute’s exemptions only if the bulk substance it is made from has a USP monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A Bulks List. A substance meeting none of those three is not banned by name. Compounding it falls outside the exemptions, which makes the resulting product an unapproved new drug and exposes the pharmacy to FDA enforcement. That is an enforcement posture, not a criminal prohibition, and the distinction matters when you read a vendor claiming the compound is legal.
Substances reach that list through a public nomination and review process, with the Pharmacy Compounding Advisory Committee advising the agency (Federal Register, 2024). FDA added AOD-9604 to 503A Category 2 on September 29, 2023 and removed it on September 27, 2024, because the nominations were withdrawn. On December 4, 2024 the committee voted 12 to 0 against adding it to the Bulks List, as FDA had proposed.